Comparative Pharmacology
Head-to-head clinical analysis: ESKALITH versus LITHANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESKALITH versus LITHANE.
ESKALITH vs LITHANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lithium modulates neurotransmission by inhibiting inositol monophosphatase, leading to reduced phosphoinositide signaling; also inhibits glycogen synthase kinase-3 (GSK-3) and alters neuronal excitability via effects on sodium transport and neurotransmitter release.
Lithium is thought to modulate neurotransmitter release and second messenger systems, including inhibition of inositol monophosphatase and alterations in G-protein signaling, though exact mechanism in bipolar disorder is unclear.
Lithium carbonate extended-release: 300-600 mg orally twice daily, titrated to serum levels 0.6-1.2 mEq/L. Immediate-release: 300-600 mg three times daily.
300-600 mg orally 3 times daily; usual therapeutic serum lithium level 0.6-1.2 mEq/L. Extended-release formulations given 2-3 times daily.
None Documented
None Documented
Terminal elimination half-life: 18-24 hours (range 12-27 hours) in adults; may be prolonged in elderly or renal impairment. Steady-state achieved in 5-7 days.
18-24 hours (single dose); 24-36 hours after chronic dosing; prolonged in elderly or renal impairment.
Renal: >95% excreted unchanged in urine. Biliary/fecal: negligible (<1%).
Renal: >95% unchanged; tubular reabsorption parallels sodium; negligible biliary/fecal.
Category C
Category C
Mood Stabilizer
Mood Stabilizer